March 2026
M	T	W	T	F	S	S
	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31

Abdulrahman Nasiri։ Decade of Evidence Supports ASCT2 in Relapsed Multiple Myeloma

Abdulrahman Nasiri/LinkedIn, Mostafa Faisal Mohammed Saleh/LinkedIn

Mar 2, 2026, 15:42

Abdulrahman Nasiri։ Decade of Evidence Supports ASCT2 in Relapsed Multiple Myeloma

Abdulrahman Nasiri, Assistant Professor of Medicine and Hematology at Imam Mohammad Ibn Saud Islamic University, shared Mostafa Faisal Mohammed Saleh’s post on LinkedIn, adding:

”Honored to contribute to this review published in Current Oncology MDPI, evaluating a decade of evidence on second or salvage autologous stem cell transplantation in relapsed multiple myeloma.

This work reinforces that ASCT2 remains a clinically meaningful, risk-adapted option for selected patients, particularly those with prolonged first remission and chemosensitive relapse, even in the era of CAR-T and bispecific antibodies.

Grateful to collaborate with distinguished colleagues Marwa Nassar, Nourah Alzaidy, Amr Hanbali, Mahmoud Aljurf, and Mostafa Faisal Mohammed Saleh.

It was a privilege to work together on this important analysis.”

Mostafa Faisal Mohammed Saleh, Associate professor of Clinical Hematology and HSCT at Assiut University, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:

”Our recent review just out in Current Oncology: ASCT2 in relapsed MM (2016 – 2026) across14 key studies.
Feasible and safe: NRM 1–4% (day 100–1y) across large registries (n=305–975).
Median PFS 9.8–30.2 mo; OS ~30 to >80 mo depending on risk.
Interval ≥24 mo from ASCT1 = strongest predictor → PFS 17–45 mo; OS >60–80 mo in favorable subsets.
Maintenance matters: lenalidomide PFS 41 vs 21.6 mo; carfilzomib-dex TTP 25.1 vs 16.7 mo.
Phase III GMMG ReLApsE: no PFS/OS superiority (20.5 vs 19.3 mo; OS 67.1 vs 62.7) → selection is key.
In the CAR-T/bispecific era, ASCT2 = risk-adapted consolidation or bridge — not routine salvage.”

Title: Salvage or Second Autologous SCT in Relapsed Multiple Myeloma (2016–2026): A Decade in Review

Authors: Marwa Nassar, Nourah Alzaidy, Abdulrahman Nasiri, Amr Hanbali, Mahmoud A. Aljurf, Mostafa F. Mohammed Saleh

Read the Full Article on Current Oncology․

Abdulrahman Nasiri։ Decade of Evidence Supports ASCT2 in Relapsed Multiple Myeloma

Stay updated on all scientific advances with Hemostasis Today.

Abdulrahman Nasiri Amr Hanbali ASCT2 CAR-T Current Oncology Health Hematology Hemostasis News Hemostasis Today Mahmoud A. Aljurf Marwa Nassar Medicine Mostafa F. Mohammed Saleh multiple myeloma Nourah Alzaidy

'

Abdul Mannan: Paradox of Bleeding and Clotting in Uremic Coagulopathy

'

Mark Crowther: How Artificial Intelligence Is Entering The Field of Hematology

'

Akshat Jain: Elevating Equity in Diagnosis, Care, and Research on World Rare Disease Day 2026

'

Isabel Bär: A Novel Gene Therapy Strategy for Heterozygous VWD

'

WFH Acknowledges BioMarin’s Decision to Discontinue ROCTAVIAN